Xilio Therapeutics Inc (XLO)

May 22, 2026

XLO Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts SharesCommunity Buy Signals - Newser

May 22, 2026

May 21, 2026

Is Xilio Therapeutics (XLO) Still a Buy After +2.89% Rally? 2026-05-21Wyckoff Upthrust - Newser

May 21, 2026

May 19, 2026

Xilio Therapeutics (XLO) Crushes Q1 2026 Estimates — EPS $-0.58 Tops ViewsHigh Interest Stocks - Newser

May 19, 2026

May 18, 2026

Cancer Stocks That Are Advancing the Future of Oncology Care - TradingView

May 18, 2026

May 17, 2026

Xilio Therapeutics, Inc. (XLO) reports Q1 loss, beats revenue estimates - MSN

May 17, 2026

May 17, 2026

Xilio Therapeutics (XLO) Stock Analysis: Falls -5.11%, Watching $7.94 2026-05-17Technical Analysis - Newser

May 17, 2026

May 16, 2026

Xilio Therapeutics (XLO) upgraded to buy: What does it mean for the stock? - MSN

May 16, 2026

May 15, 2026

OrbiMed group discloses stakes in Xilio Therapeutics (NASDAQ: XLO), up to 9.99% - Stock Titan

May 15, 2026

May 15, 2026

Bain Capital entities report 9.99% stake in Xilio Therapeutics (XLO) - Stock Titan

May 15, 2026

May 15, 2026

Point72 (XLO) files 13G/A showing 0% stake in Xilio Therapeutics - Stock Titan

May 15, 2026

May 15, 2026

Sirenia and Alex Silverstein report 9.9% stake in Xilio (NASDAQ: XLO) - Stock Titan

May 15, 2026

May 14, 2026

TradingKey - TradingKey

May 14, 2026

May 12, 2026

Xilio Therapeutics Releases Q1 2026 Financial Results - AlphaStreet

May 12, 2026

May 12, 2026

Xilio Therapeutics, Inc. 2026 Q1 Quarterly Report: Financials, Risk Factors, and Business Overview - Minichart

May 12, 2026

May 12, 2026

XLO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

May 12, 2026

May 12, 2026

Sagimet Biosciences Releases Q1 2026 Financial Results - AlphaStreet

May 12, 2026

May 12, 2026

Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance

May 12, 2026

May 12, 2026

Xilio Therapeutics Reports Q1 2026 Financial Results, Advances Pipeline with XTX501 IND Filing and AbbVie Milestone Extension - Minichart

May 12, 2026

May 12, 2026

Xilio Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

May 12, 2026

May 12, 2026

According to documents submitted to the U.S. Securities and Exchange Commission (SEC), biotechnology company Xilio Therapeutics Inc. has entered into a common stock sales agreement with investment bank Leerink Partners LLC. - Bitget

May 12, 2026

May 12, 2026

Xilio Therapeutics (NASDAQ: XLO) files $250M shelf, includes $17.22M ATM - Stock Titan

May 12, 2026

May 12, 2026

Xilio Therapeutics, Inc. 1Q 2026: Revenue $12.6M, EPS $(0.58) — 10-Q Summary - TradingView

May 12, 2026

May 12, 2026

Xilio Therapeutics (XLO) boosts Q1 2026 collaboration revenue and extends cash runway into 2028 - Stock Titan

May 12, 2026

May 12, 2026

Xilio Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 12, 2026

May 12, 2026

Xilio (Nasdaq: XLO) Q1 2026 loss narrows as cash runway extends to 2028 - Stock Titan

May 12, 2026

May 12, 2026

Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and ... - Caledonian Record

May 12, 2026

May 12, 2026

Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates - GlobeNewswire

May 12, 2026

May 11, 2026

XLO (Xilio Therapeutics) swings to profit, crushing estimates by 147.7 percent as stock gains.Expert Momentum Signals - newser.com

May 11, 2026

May 11, 2026

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 7, 2026 - marketscreener.com

May 11, 2026

May 10, 2026

Number of shareholders of Xilio Therapeutics, Inc. – NASDAQ:XLO - TradingView

May 10, 2026

May 08, 2026

XLO Xilio Therapeutics smashes Q4 earnings with 147.7% beat, 589.9% revenue surge, yet shares fall 1.14%.Expert Entry Points - newser.com

May 08, 2026

May 07, 2026

Xilio Therapeutics Grants Options for 146,800 Shares to New Employees - geneonline.com

May 07, 2026

May 07, 2026

New Xilio hire gets stock options for 1,982 shares at $8.32 - Stock Titan

May 07, 2026

May 06, 2026

Actuate Therapeutics Adds Oncology Expert to Board Leadership - TipRanks

May 06, 2026

May 06, 2026

Actuate Therapeutics appoints Martin Huber to board By Investing.com - Investing.com Australia

May 06, 2026

May 06, 2026

Xilio Therapeutics Inc expected to post a loss of 66 cents a shareEarnings Preview - TradingView

May 06, 2026

Apr 30, 2026

Net current asset value per share of Xilio Therapeutics, Inc. – NASDAQ:XLO - TradingView

Apr 30, 2026

Apr 30, 2026

XLO Q1'26 Earnings: revenue estimate is 8.52M USD - TradingView

Apr 30, 2026

Apr 30, 2026

Xilio Therapeutics (XLO) price target decreased by 28.57% to 20.40 - MSN

Apr 30, 2026

Apr 28, 2026

[ARS] Xilio Therapeutics, Inc. SEC Filing - Stock Titan

Apr 28, 2026

Apr 28, 2026

Xilio Therapeutics | ARS: Annual Report to Security Holders - Moomoo

Apr 28, 2026

Apr 28, 2026

Stock plan change and virtual 2026 annual meeting at Xilio (XLO) - Stock Titan

Apr 28, 2026

Apr 27, 2026

What failed trades Xilio Therapeutics (XLO)? (Slight Gain) 2026-04-27Market Expert Watchlist - Newser

Apr 27, 2026

Apr 21, 2026

Xilio Therapeutics Announces 1-for-14 Reverse Stock Split - WFXG

Apr 21, 2026

Apr 21, 2026

Xilio Therapeutics | 8-K: Current report - Moomoo

Apr 21, 2026

Apr 18, 2026

Xilio Therapeutics (XLO) Stock: Growth Outlook (+2.63%) 2026-04-18Sector Analysis - Xã Vĩnh Công

Apr 18, 2026

Apr 18, 2026

Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2 - Sahm

Apr 18, 2026

Apr 18, 2026

XLO: Xilio Therapeutics Presents Promising Preclinical Findings for XTX601 at AACR - GuruFocus

Apr 18, 2026

Apr 17, 2026

Xilio announces new preclinical data for XTX601 at AACR - TipRanks

Apr 17, 2026

Apr 17, 2026

Xilio Therapeutics appoints Cheryl Blanchard to board By Investing.com - Investing.com India

Apr 17, 2026